These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 36085579)

  • 1. Implementation of sacral neuromodulation for urinary indications. A Danish prospective study during the initial 15 months of a new service in a tertiary referral hospital.
    Kobberø H; Andersen M; Andersen K; Pedersen TB; Poulsen MH
    Scand J Urol; 2022; 56(5-6):404-411. PubMed ID: 36085579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of sacral neuromodulation in male patients with overactive bladder, chronic pelvic pain, and fecal incontinence.
    Ferreira R; Alwashmi E; Otis-Chapados S; Bhojani N; Zorn KC; Chughtai B; Elterman DS
    Can J Urol; 2024 Aug; 31(4):11943-11949. PubMed ID: 39217518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sacral neuromodulation treatment for urinary voiding dysfunctions: results of treatment with the largest single-center series in a tertiary referral center in Turkey.
    Kütükoğlu MU; Altuntaş T; Şahin B; Onur AR
    Turk J Med Sci; 2023 Feb; 53(1):206-210. PubMed ID: 36945940
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sacral Neuromodulation with the InterStim™ System for Intractable Lower Urinary Tract Dysfunctions (SOUNDS): Results of Clinical Effectiveness, Quality of Life, Patient-Reported Outcomes and Safety in a French Multicenter Observational Study.
    Chartier-Kastler E; Le Normand L; Ruffion A; Dargent F; Braguet R; Saussine C; Tanneau Y; Graziana JP; Ragni E; Rabut B; Rousseau T; Biardeau X; Gamé X; Pierrevelcin J; Brassart E; Fourmarier M; Stoica G; Berrogain N; Yaghi N; Pecoux F; Capon G; Ferchaud J; Peyrat L; Bryckaert PE; Karsenty G; Melotti A; Abouihia A; Keller DUJ; Cornu JN
    Eur Urol Focus; 2021 Nov; 7(6):1430-1437. PubMed ID: 32907782
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preliminary analysis of stimulation parameters for sacral neuromodulation in different indications: a multicenter retrospective cohort study from China.
    Meng L; Yan Z; Wang X; Zhang Y; Zhu Z; Zhu W; Ling Q; Sun X; Gu Y; Lv J; Li Y
    Int J Surg; 2024 Jun; 110(6):3536-3542. PubMed ID: 38445489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Invasive neurostimulation in neuro-urology: state of the art].
    Kurze I; Böthig R; van Ophoven A
    Aktuelle Urol; 2024 Aug; 55(4):351-364. PubMed ID: 38631373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sacral neuromodulation for lower urinary tract dysfunction.
    Van Kerrebroeck PE; Marcelissen TA
    World J Urol; 2012 Aug; 30(4):445-50. PubMed ID: 21989816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Sacral neuromodulation in under- and overactive detrusor-quo vadis? : Principles and developments].
    Girtner F; Burger M; Mayr R
    Urologe A; 2019 Jun; 58(6):634-639. PubMed ID: 31139864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of sacral neuromodulation on urological diseases: a multicentric research project.
    Cardarelli S; D'Elia C; Cerruto MA; Curti P; Ostardo E; Signorello D; Pastorello M; Caleffi G; Molon A; Artibani W
    Urologia; 2012; 79(2):90-6. PubMed ID: 22610844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-Year Outcomes of Sacral Neuromodulation Versus OnabotulinumtoxinA for Refractory Urgency Urinary Incontinence: A Randomized Trial.
    Amundsen CL; Komesu YM; Chermansky C; Gregory WT; Myers DL; Honeycutt EF; Vasavada SP; Nguyen JN; Wilson TS; Harvie HS; Wallace D;
    Eur Urol; 2018 Jul; 74(1):66-73. PubMed ID: 29482936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Sacral neuromodulation in urology. The emperor's new clothes or effective high-tech medicine?].
    Hoda MR; Fornara P
    Urologe A; 2010 Oct; 49(10):1254-9. PubMed ID: 20859609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Sacral neuromodulation as second-line treatment strategy for lower urinary tract symptoms of various aetiologies: experience of a German high-volume clinic].
    Otto W; Nowrotek A; Burger M; Wieland WF; Rößler W; Denzinger S
    Aktuelle Urol; 2012 May; 43(3):162-6. PubMed ID: 22639025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sacral neuromodulation for the treatment of overactive bladder: systematic review and future prospects.
    Tilborghs S; De Wachter S
    Expert Rev Med Devices; 2022 Feb; 19(2):161-187. PubMed ID: 35061951
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sacral Neuromodulation in Patients With Neurogenic Lower Urinary Tract Dysfunction: A Multicenter Retrospective Study From China.
    Masood I; Chen Q; Li J; Xu Z; Ying X; Wang Y; Chen G; Liao L
    Neuromodulation; 2021 Oct; 24(7):1278-1283. PubMed ID: 33908130
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Five-year Results from the Prospective, Multicenter, Observational SOUNDS Study of Patients with Overactive Bladder Treated with the InterStim System for Sacral Neuromodulation.
    Chartier-Kastler E; Le Normand L; Ruffion A; Saussine C; Braguet R; Rabut B; Ragni E; Perrouin-Verbe MA; Pierrevelcin J; Rousseau T; Gamé X; Tanneau Y; Dargent F; Biardeau X; Graziana JP; Stoica G; Brassart E; Fourmarier M; Yaghi N; Capon G; Ferchaud J; Berrogain N; Peyrat L; Pecoux F; Bryckaert PE; Karsenty G; Song S; Keller DUJ; Cornu JN
    Eur Urol Focus; 2023 Sep; 9(5):765-772. PubMed ID: 37019729
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Detailed Investigation of Bladder Diary Parameters During Sacral Neuromodulation in Patients With Overactive Symptoms.
    Van de Borne S; Tilborghs S; Vaganée D; Vermandel A; De Wachter S
    Neuromodulation; 2023 Dec; 26(8):1831-1835. PubMed ID: 36266179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sacral Neuromodulation Changes Pelvic Floor Activity in Overactive Bladder Patients-Possible New Insights in Mechanism of Action: A Pilot Study.
    Voorham J; Vaganée D; Voorham-van der Zalm P; Lycklama À Nijeholt G; Putter H; De Wachter S
    Neuromodulation; 2022 Dec; 25(8):1180-1186. PubMed ID: 34547159
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective, multicenter study of a novel, miniaturized rechargeable sacral neuromodulation system: 12-month results from the RELAX-OAB study.
    Blok B; Van Kerrebroeck P; de Wachter S; Ruffion A; Van der Aa F; Jairam R; Perrouin-Verbe MA; Elneil S
    Neurourol Urodyn; 2019 Feb; 38(2):689-695. PubMed ID: 30592526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Functional results and satisfaction in 44 patients after implantation of a NS3-type sacral neurostimulator for refractory idiopathic overactive bladder followed at 43 months, single-center series].
    Msika J; Kalantan M; Larre S; Leon P
    Prog Urol; 2021 Oct; 31(12):725-731. PubMed ID: 33962849
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
    Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
    Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.